吉西他滨联合卡铂治疗老年晚期非小细胞肺癌

目的观察吉西他滨加卡铂联合方案治疗老年晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法老年和非老年组各47例晚期NSCLC接受化疗治疗,方案为吉西他滨1000mg/m2静脉滴注30min第1、8天,卡铂AUC5静脉滴注,第1天,21～28d为一个周期,每例患者至少化疗2周期。结果老年组与非老年组有效率分别为40.4%与44.7%,无显著性差异(P<0.05);不良反应主要为骨髓抑制。结论吉西他滨加卡铂联合方案治疗老年晚期NSCLC有效率高,毒性可以耐受,值得临床推广。

Gemcitabine combined carbopaltin regime in the treatment of elderly patients with advanced non-small cell lung cancer

Objective To evaluate the efficacy and toxicity of gemcitabine combined with carbopaltin in elderly patients with advanced NSCLC. Methods The 47 elderly patients with advanced NSCLC were treated with the combined chemotherapy (gemcitabine 1 000mg/m2 on the 1st, 8th day and carboplatin AUC5 on the 1st day) . Each patient was given at least 2 cycles at an interval of 21-28 days, and the effect was then evaluated. Results The effective rates of observation and controlled groups was 40.4% and 44.7%, the difference was not significant (P<0.05). The main adverse reactions was bone marrow depression. Conclusion Gemcitabine combined with carboplatin is effective and well tolerated for elderly patients with NSCLC.